moderate Severity

Pellitory of the Wall Allergy: The Mediterranean Weed That Causes Severe Hay Fever

Pellitory of the wall allergy is an IgE-mediated reaction to pollen from Parietaria judaica and Parietaria officinalis, two species of the nettle family (Urticaceae) that are among the most potent aeroallergens in Mediterranean climates. The major allergen Par j 1 is a lipid transfer protein (LTP) that triggers severe rhinoconjunctivitis and asthma in sensitized individuals, with symptoms lasting from early spring through late autumn. Unlike most weed pollens, Parietaria has an exceptionally long pollen season (February–November in Mediterranean regions) and produces highly allergenic pollen that remains airborne even in humid conditions. The weed has naturalized in parts of California, Oregon, and the US Gulf Coast, where it is increasingly recognized as a cause of persistent summer hay fever. Allergen immunotherapy with standardized Parietaria extracts is the only disease-modifying treatment and has been shown in clinical trials to reduce symptom scores by 60–85%.

moderatePeak: Feb–Nov (Mediterranean)Updated July 13, 2026

Free Β· 5 min Β· Insurance accepted

Reviewed by Dr. Chet Tharpe, M.D.
As seen inUSA TODAYMen's HealthCBSForbes
The numbers
Headline stat
0–30%
US prevalence
Peak season
Feb–Nov (Mediterranean)
Symptoms tracked
0
Treatment paths
0
Peer-reviewed sources
0
01Overview

What Is Pellitory of the Wall Allergy?

Pellitory of the wall allergy is a potentially severe IgE-mediated respiratory allergy caused by pollen from Parietaria judaica (spreading pellitory) and Parietaria officinalis (upright pellitory), two species in the Urticaceae (nettle) family.

Despite its common name suggesting a minor weed, Parietaria pollen is one of the most potent aeroallergens in Mediterranean climates β€” responsible for 10–30% of seasonal allergic rhinitis cases in Italy, Spain, Greece, and southern France. The major allergen, Par j 1, is a lipid transfer protein (LTP) that is exceptionally stable and resistant to degradation, allowing it to remain allergenic in the environment for extended periods. Unlike most weed pollens that have a defined 4–8 week season, Parietaria has an extraordinarily long pollen season spanning February through November in Mediterranean regions, with multiple peaks corresponding to successive flowering cycles.

The weed has naturalized in California, Oregon, and the US Gulf Coast, where it is increasingly recognized as a cause of persistent summer hay fever that does not respond to standard antihistamine therapy alone.

02Symptoms

Symptoms of Pellitory of the Wall Allergy

Recognizing symptoms early helps you get the right treatment faster.

Sneezing

moderate

Repetitive, paroxysmal sneezing is a hallmark symptom, often occurring in bursts upon waking or after outdoor exposure during peak pollen times.

Profuse watery rhinorrhea

moderate

Copious clear nasal discharge is characteristic of Parietaria allergy, often requiring frequent tissue use and causing significant daily disruption.

Nasal congestion

moderate

Mucosal swelling causes bilateral nasal blockage that can interfere with sleep, leading to fatigue and reduced quality of life during the long pollen season.

Intense ocular itching and tearing

moderate

Allergic conjunctivitis with severe itch, redness, and watery discharge is common; patients often rub their eyes excessively, leading to periorbital swelling.

Palatal and ear itching

mild

Deep itch in the roof of the mouth and ear canals is a characteristic feature of weed pollen allergy, distinct from viral rhinitis.

Asthma symptoms (wheezing, chest tightness, cough)

severe

40–60% of Parietaria-allergic patients develop asthma, with symptoms closely tracking pollen counts. Nocturnal cough and exercise-induced wheezing are common.

Post-nasal drip and chronic cough

mild

Persistent mucus drainage from the nasal passages into the throat causes throat clearing, cough, and a sensation of a lump in the throat.

Fatigue and malaise

mild

Chronic allergic inflammation and sleep disruption from nasal congestion lead to daytime fatigue, reduced concentration, and decreased productivity.

When to see a doctor

Pellitory of the wall allergy produces classic IgE-mediated rhinoconjunctivitis symptoms that are often more severe and persistent than those caused by other weed pollens. The hallmark is a prolonged symptom period lasting 8–10 months, with patients experiencing daily sneezing, profuse watery rhinorrhea, nasal congestion, and intense ocular itching. The severity is attributed to the LTP nature of Par j 1, which triggers a stronger and more sustained inflammatory response than typical pollen allergens. Many patients report that symptoms do not respond adequately to standard antihistamine doses, requiring combination therapy with intranasal corticosteroids. Asthma is a common comorbidity β€” studies from Mediterranean populations show that 40–60% of Parietaria-allergic patients have concurrent asthma, with exacerbations closely tracking pollen counts. The long season means that patients with Parietaria allergy often have persistent airway inflammation that can lead to asthma development even in those who initially present with rhinitis alone. If you experience chest tightness, wheezing, or difficulty breathing during the Parietaria pollen season, seek emergency care immediately.

Pellitory of the Wall and Asthma Risk

Pellitory of the wall allergy has one of the strongest associations with asthma among all weed pollen allergies. Studies from Mediterranean populations consistently show that 40–60% of Parietaria-allergic patients have concurrent asthma, compared to 20–30% for other pollen allergies. The LTP nature of Par j 1 is believed to contribute to this high asthma prevalence β€” LTP allergens are highly stable and can penetrate deep into the lower airways, triggering bronchial inflammation even at low pollen concentrations. The extraordinarily long pollen season (8–10 months) means that patients experience persistent airway inflammation rather than the intermittent exposure typical of other seasonal allergens. This chronic inflammation can lead to airway remodeling and the development of asthma even in patients who initially present with rhinitis alone. The 'united airway' concept is particularly relevant for Parietaria allergy: treating the upper airway inflammation with intranasal corticosteroids and allergen immunotherapy has been shown to reduce asthma symptoms and medication use in Parietaria-allergic patients.

If left untreated

Potential Complications of Pellitory of the Wall Allergy

Untreated or inadequately managed Parietaria allergy can lead to several clinically significant complications. The most common is the development of asthma in patients who initially present with rhinitis alone β€” the persistent airway inflammation during the 8–10 month pollen season drives the atopic march from upper to lower airways. Chronic sinusitis is another frequent complication, as prolonged nasal inflammation impairs sinus drainage and creates conditions favorable for bacterial superinfection. The long season also contributes to the development of nasal polyps in some patients, particularly those with concurrent aspirin sensitivity or asthma. Sleep disturbance from nocturnal nasal congestion is a major quality-of-life issue, leading to daytime fatigue, reduced cognitive function, and impaired work or school performance. The LTP nature of Par j 1 also raises the possibility of cross-reactive food allergies β€” patients with Parietaria allergy may develop oral allergy syndrome to LTP-containing foods such as peach, apple, hazelnut, and peanut, though this is less well-documented than the pollen-food syndrome seen with birch or ragweed.

Asthma development

40–60% of Parietaria-allergic patients develop asthma, driven by the long pollen season and deep airway penetration of stable LTP allergens.

Chronic sinusitis

Persistent nasal inflammation impairs sinus drainage, leading to recurrent or chronic bacterial sinusitis requiring antibiotic or surgical intervention.

Nasal polyps

Chronic inflammation from the long pollen season can contribute to the development of nasal polyps, particularly in patients with aspirin sensitivity.

Sleep disturbance and daytime fatigue

Nocturnal nasal congestion causes sleep fragmentation, leading to daytime sleepiness, reduced concentration, and impaired quality of life.

LTP cross-reactive food allergy

Par j 1 is a lipid transfer protein; patients may develop oral allergy syndrome to LTP-containing foods such as peach, apple, hazelnut, and peanut.

03Why it happens

What Causes Pellitory of the Wall Reactions?

Pellitory of the wall reactions are caused by IgE-mediated sensitization to pollen proteins from Parietaria judaica and Parietaria officinalis. The major allergen Par j 1 is a non-specific lipid transfer protein (nsLTP) belonging to the LTP family β€” a group of proteins that are highly stable, resistant to proteolysis and heat, and capable of triggering strong IgE responses.

Common Species

Spreading pellitory / wall pellitory

Parietaria judaica

Upright pellitory / common pellitory

Parietaria officinalis

Pennsylvania pellitory (native US species, less allergenic)

Parietaria pensylvanica

Pellitory of the wall allergy follows the classic Type I (IgE-mediated) hypersensitivity pathway. Upon first exposure, the LTP allergens Par j 1 and Par j 2 are processed by antigen-presenting cells and presented to T-helper cells, which stimulate B cells to produce specific IgE antibodies. These IgE antibodies bind to high-affinity FcΞ΅RI receptors on mast cells and basophils, sensitizing the immune system. Upon re-exposure, inhaled Parietaria pollen cross-links these surface-bound IgE molecules, triggering mast cell degranulation with release of histamine, leukotrienes, and prostaglandins that produce rhinoconjunctivitis symptoms within minutes. The LTP structure of Par j 1 contributes to its high allergenicity because LTPs are resistant to proteolytic degradation in the respiratory mucosa, allowing prolonged antigen presentation and stronger T-cell responses. The late-phase response, occurring 4–12 hours after exposure, involves eosinophil and neutrophil recruitment driven by cytokines (IL-4, IL-5, IL-13) released from activated Th2 cells.

Par j 1 is the dominant allergen, recognized by over 95% of Parietaria-allergic patients. A second allergen, Par j 2, is also an LTP but with slightly different IgE-binding properties.

The LTP nature of these allergens is clinically significant because LTPs are known to cause more persistent and severe allergic responses compared to other pollen allergens, and they are resistant to the degradation that typically limits pollen allergenicity in humid conditions. This explains why Parietaria pollen remains allergenic even during coastal fog and high humidity β€” conditions that normally reduce the allergenicity of other pollens.

The pollen grains themselves are small (12–16 microns) and easily become airborne, remaining suspended for long periods. The plant produces enormous quantities of pollen β€” a single plant can release millions of pollen grains over its flowering season.

Who's most affected

Risk factors to watch for

01

Residence in Mediterranean climate regions

Highest risk in Italy, Spain, Greece, southern France, coastal California, Oregon, and the US Gulf Coast where Parietaria has naturalized.

02

Living near old stone walls or buildings

Parietaria judaica grows preferentially in cracks in stone walls, old buildings, and rocky soil β€” proximity to these habitats increases exposure.

03

Occupational exposure (gardeners, masons, construction workers)

Workers who disturb stone walls, rubble, or overgrown areas have elevated exposure to Parietaria pollen and plant debris.

04

LTP-sensitization phenotype

Patients with LTP-driven allergies (including food LTP allergies to peach, apple, or hazelnut) may show cross-reactive IgE responses to Par j 1.

The Allergy Cascade

1.Exposure

Allergen contact

2.Detection

Immune recognition

3.IgE Response

Antibody production

4.Mast Cells

Histamine release

5.Symptoms

Allergic reaction

05Diagnosis

How to Diagnose Pellitory of the Wall Allergy

Diagnosing Parietaria allergy requires a combination of clinical history, geographic context, and standard allergy testing. The clinical history is often suggestive: a patient living in a Mediterranean climate region (coastal California, Oregon, Gulf Coast) who experiences severe rhinoconjunctivitis from early spring through late autumn, with symptoms that do not fully respond to antihistamines, should raise suspicion for Parietaria allergy. The diagnosis is confirmed by skin prick testing with standardized Parietaria extract, which is commercially available in the US and Europe. Specific IgE blood testing (ImmunoCAP) for Parietaria judaica is also widely available and highly sensitive. Molecular component-resolved diagnostics can identify IgE antibodies to Par j 1 and Par j 2, which can help distinguish primary Parietaria sensitization from cross-reactivity with other LTP allergens. At-home allergy testing services such as Curex offer panels covering 40+ environmental allergens with results typically within 5 days, providing a convenient option for patients in regions where Parietaria is prevalent to map their full sensitization profile.

Skin prick test with Parietaria extract

A standardized extract of Parietaria judaica pollen is applied to the skin via a small lancet prick; a wheal β‰₯3 mm larger than the negative control indicates sensitization.

Specific IgE blood test (ImmunoCAP)

Measures circulating IgE antibodies to Parietaria judaica in a blood sample; results are reported in kU/L with standard reference ranges.

Component-resolved diagnostics (Par j 1, Par j 2)

Molecular testing for IgE to individual Parietaria allergens Par j 1 and Par j 2; helps distinguish primary sensitization from cross-reactivity.

At-home testing

Test from home with Curex

Skip the clinic visit. Curex sends an at-home allergy test kit to your door, and a board-certified allergist reviews your results to build a personalized treatment plan.

Take the allergy quiz
Insurance acceptedBoard-certified allergists
06Treatment

Treatment Options for Pellitory of the Wall Allergy

See how different approaches stack up for managing your allergy symptoms long-term.

Treatment for Parietaria allergy follows the standard stepwise approach for seasonal allergic rhinitis, but with important modifications due to the long pollen season and the severity of symptoms. The foundation is pharmacotherapy β€” intranasal corticosteroids are first-line therapy, often combined with oral antihistamines and antihistamine eye drops for comprehensive symptom control. Because the season lasts 8–10 months, patients typically require continuous daily medication rather than as-needed use. For patients with moderate-to-severe symptoms or those who develop asthma, allergen immunotherapy with standardized Parietaria extract is the only disease-modifying treatment and has been shown in clinical trials to reduce symptom scores by 60–85%. The long season means that patients should be counseled on the importance of consistent medication adherence β€” intermittent use during peak weeks is less effective than continuous treatment throughout the pollen season. Patients should also be aware that the LTP nature of Par j 1 means that symptoms may persist even on days with moderate pollen counts, unlike other weed allergies where symptoms are more closely tied to high-count days.

Intranasal corticosteroids

First-line therapy for Parietaria allergy; reduce mucosal inflammation, congestion, and rhinorrhea more effectively than antihistamines alone. Essential for the long season.

Flonase (fluticasone), Nasonex (mometasone), Nasacort (triamcinolone), Rhinocort (budesonide)

Meta-analyses demonstrate 30–40% greater symptom reduction vs antihistamine monotherapy

Second-generation oral antihistamines

Non-sedating H1 antihistamines reduce sneezing, itch, and rhinorrhea; may need higher or more frequent dosing for Parietaria due to LTP-driven severity.

Zyrtec (cetirizine), Claritin (loratadine), Allegra (fexofenadine), Xyzal (levocetirizine)

Studies show 50–60% reduction in rhinitis symptom scores, but may be less effective for Parietaria than other pollens

Antihistamine eye drops

Topical ophthalmic antihistamines rapidly relieve allergic conjunctivitis symptoms independent of oral medication; essential for patients with severe ocular symptoms.

Pataday (olopatadine), Alaway (ketotifen), Lastacaft (alcaftadine)

Evidence shows fast onset (within minutes) and effective itch/redness control

Leukotriene receptor antagonists

Montelukast blocks leukotriene receptors, reducing both nasal and bronchial inflammation; particularly useful for patients with concurrent asthma.

Singulair (montelukast)

Modest benefit for rhinitis; more effective for asthma symptoms in Parietaria-allergic patients

Allergen immunotherapy (Parietaria extract)

The only disease-modifying treatment for Parietaria allergy. Standardized Parietaria extract is available for both SCIT and SLIT in Europe; SLIT is increasingly available in the US.

Standardized Parietaria judaica allergen extract

Clinical trials show 60–85% reduction in rhinoconjunctivitis symptom scores and medication use

Traditional

  • NoTreats root cause
  • NoLong-lasting relief
  • YesAt-home treatment
  • YesNo office visits
  • YesLow side effects
  • PartialEstimated cost

Allergy Shots (SCIT)

  • YesTreats root cause
  • YesLong-lasting relief
  • NoAt-home treatment
  • NoNo office visits
  • PartialLow side effects
  • PartialEstimated cost

Immunotherapy (SLIT)

Recommended
  • YesTreats root cause
  • YesLong-lasting relief
  • YesAt-home treatment
  • YesNo office visits
  • YesLow side effects
  • YesEstimated cost
Immunotherapy

Immunotherapy for Pellitory of the Wall Allergy

Instead of masking symptoms, immunotherapy retrains your immune system.

If you've been managing Parietaria allergy with daily antihistamines and nasal sprays for 8 months of the year and still experiencing breakthrough symptoms, allergen immunotherapy offers a fundamentally different approach β€” one that addresses the immune system's underlying sensitivity rather than just suppressing symptoms. Parietaria is one of the few weed pollens for which standardized immunotherapy extracts are commercially available, reflecting its clinical importance in Mediterranean regions and increasingly in California. Both subcutaneous immunotherapy (allergy shots) and sublingual immunotherapy (SLIT drops) have been studied for Parietaria allergy. European clinical trials demonstrate that SLIT with Parietaria extract reduces rhinoconjunctivitis symptom scores by 60–85% and medication use by 50–70%, with benefits persisting for years after treatment completion. The LTP nature of Par j 1 means that immunotherapy may be particularly effective because the stable LTP protein structure allows for robust immune tolerance induction. For patients in the US, sublingual immunotherapy drops, offered by providers like Curex with plan-specific pricing (https://getcurex.com/learn/curex-pricing), provide a convenient at-home option that eliminates the need for weekly clinic visits. In a real-world Curex study of 2,897 patients on at-home sublingual immunotherapy (Tharpe et al., Frontiers in Allergy, 2026), clinically meaningful symptom improvement rose to 45% of patients by two years, quality-of-life improvement reached 90.7%, and adherence was over 90% with no anaphylaxis reported. This is especially practical for patients managing the 8–10 month Parietaria season, as the immunotherapy course can be initiated before the season begins and continued through the year. Most insurance plans cover SLIT for Parietaria allergy when prescribed by a board-certified allergist.

1Step 1

Confirm Parietaria sensitization

Skin prick testing or specific IgE blood test confirms Parietaria as the primary sensitizing allergen, ruling out cross-reactivity with other LTP allergens.

2Step 2

Component-resolved diagnostics (optional)

Testing for Par j 1 and Par j 2 IgE antibodies provides mechanistic precision and helps predict immunotherapy response.

3Step 3

Custom immunotherapy formulation

Standardized Parietaria extract is formulated into allergen drops or shots based on the patient's sensitization profile and symptom severity.

4Step 4

3–5 year desensitization course

Gradually increasing doses build immune tolerance; most patients experience significant improvement within 6–12 months, with sustained benefit after completion.

β€œClinical trials in Parietaria-allergic populations show 60–85% reduction in rhinoconjunctivitis symptom scores and 50–70% reduction in medication use with allergen immunotherapy”

Curex drops

Treat your Pellitory of the Wall allergy at the source

See if at-home sublingual allergy drops fit your allergies β€” a 2-minute quiz, designed by board-certified allergists, with no needles and no clinic visits.

  • MD-led
    Board-certified allergists
  • Plan-specific
    Pricing Β· Confirm your quote
  • 50K+
    Patients treated
  • HSA/FSA
    Eligible
Living with it

Living With Pellitory of the Wall Allergy

Living with Parietaria allergy requires a structured, year-round management approach that accounts for the 8–10 month pollen season. The most important adjustment is accepting that this is not a 'spring allergy' that resolves by summer β€” it is a persistent condition that requires daily medication adherence and environmental controls for most of the year. Creating a symptom diary during the first season helps identify personal trigger thresholds and peak symptom periods, which can guide medication timing and lifestyle adjustments. For patients in coastal California, Oregon, or the Gulf Coast, understanding that the local 'weed season' is driven by Parietaria rather than ragweed or sagebrush is essential for appropriate treatment. Joining a local allergy support group or online community can provide practical tips from others managing the same condition. For patients with concurrent asthma, having a written asthma action plan that accounts for the Parietaria season is critical β€” peak flow monitoring and early escalation of controller medications during high-pollen weeks can prevent emergency department visits.

  • Accept the long season

    Parietaria allergy is not a 4–6 week spring allergy β€” it spans February through November. Adjust your expectations and medication plan accordingly.

  • Identify local Parietaria plants

    Learn to recognize Parietaria judaica growing in stone walls, old buildings, and rocky soil. Removing plants within 50 feet of your home can reduce local exposure.

  • Create a medication calendar

    Set a daily reminder for intranasal corticosteroids and antihistamines from February through November. Consistency is more effective than as-needed use during the long season.

  • Plan outdoor activities strategically

    Schedule outdoor exercise and activities for late afternoon or after rain when pollen counts are lowest. Check daily pollen forecasts before planning outdoor time.

When Does Pellitory of the Wall Pollen Peak?

Pellitory of the wall has one of the longest pollen seasons of any aeroallergen β€” spanning February through November in Mediterranean climates, with multiple flowering peaks. The plant is a perennial that flowers repeatedly from early spring through late autumn, producing fresh pollen with each flowering cycle. In Mediterranean Europe, the primary peak occurs in April–May, followed by a secondary peak in September–October. In coastal California, where the plant has naturalized, the season extends from March through November, with the highest counts typically in May–June and again in September–October. The long season is clinically significant because patients experience persistent symptoms for 8–10 months of the year, often leading to the misdiagnosis of perennial allergic rhinitis rather than seasonal allergy. Unlike many weed pollens that peak in dry weather, Parietaria pollen counts remain elevated even during humid coastal conditions due to the stability of the LTP allergens. The pollen is also capable of traveling long distances on wind currents, so patients may experience symptoms even when no visible plants are nearby.

Spring

March - June

high intensity

Summer

July - August

medium intensity

Fall

September - November

high intensity

Winter

December - February

low intensity

Preventing Pellitory of the Wall Reactions

Preventing Parietaria pollen reactions requires a proactive approach that accounts for the exceptionally long pollen season. Because the plant flowers from early spring through late autumn, avoidance strategies must be maintained for 8–10 months of the year. During the peak pollen months (April–June and September–October), staying indoors during mid-morning and early evening hours when pollen counts are highest, keeping windows closed, and using air conditioning with HEPA filtration significantly reduces indoor pollen exposure. After any outdoor activity, showering and changing clothes removes pollen trapped in hair and on clothing. The plant grows preferentially in cracks in stone walls, old buildings, and rocky soil β€” identifying and removing Parietaria plants within 50 feet of the home can substantially reduce local pollen exposure, though the small pollen grains can travel long distances on wind. Pre-treating with intranasal corticosteroids 1–2 weeks before the expected start of the pollen season (typically February in coastal California) reduces the severity of the initial inflammatory response and provides better symptom control throughout the season.

Monitor local pollen counts

Use the National Allergy Bureau or weather app pollen tracking to identify high-count days and proactively limit outdoor exposure during the 8–10 month season.

Keep windows closed year-round during season

Close windows and use air conditioning with HEPA filtration from February through November in areas where Parietaria is prevalent.

Remove Parietaria plants near the home

Identify and remove Parietaria judaica growing in cracks in stone walls, old buildings, or rocky soil within 50 feet of the home to reduce local pollen exposure.

Shower after outdoor exposure

Showering and changing clothes after time outdoors removes pollen from hair, skin, and clothing that would continue causing indoor exposure.

Pre-season medication start

Beginning intranasal corticosteroids 1–2 weeks before the expected February start of the pollen season reduces the initial inflammatory response and controls symptoms more effectively.

Wear a pollen mask during gardening

An N95 or KN95 mask worn during yard work or gardening in areas with Parietaria growth can significantly reduce inhaled pollen exposure.

Long-term outlook

Outlook for Pellitory of the Wall Allergy

The prognosis for Parietaria allergy is generally favorable with appropriate management, though the long pollen season means that untreated patients experience significant quality-of-life impairment. With consistent pharmacotherapy, most patients achieve adequate symptom control, though the LTP-driven severity may require combination therapy (intranasal corticosteroid + antihistamine + eye drops) rather than monotherapy. For patients pursuing allergen immunotherapy, the outlook is excellent β€” clinical trials demonstrate 60–85% symptom reduction with sustained benefit for years after treatment completion. The disease-modifying effect of immunotherapy is particularly valuable for Parietaria allergy because it addresses the underlying immune response rather than requiring daily medication for 8–10 months each year. Patients who develop asthma as a complication of Parietaria allergy generally respond well to standard asthma therapy, though early intervention with immunotherapy may prevent the progression from rhinitis to asthma.

What to expect

Key takeaways

01

Parietaria allergy is a significant but manageable condition with appropriate pharmacotherapy and environmental controls

02

Allergen immunotherapy with standardized Parietaria extract is the only disease-modifying treatment and offers 60–85% symptom reduction

03

The long pollen season (8–10 months) requires consistent medication adherence rather than as-needed use

04

Early immunotherapy intervention may prevent the progression from allergic rhinitis to asthma

Diet

Diet and Pellitory of the Wall Cross-Reactivity

Dietary cross-reactivity is a consideration for Parietaria allergy because the major allergen Par j 1 is a lipid transfer protein (LTP) β€” a family of proteins that are major food allergens in their own right. LTPs are found in many plant foods, including peach (Pru p 3), apple (Mal d 3), hazelnut (Cor a 8), peanut (Ara h 9), and walnut (Jug r 3). Patients with Parietaria allergy may develop IgE antibodies that cross-react with these food LTPs, leading to oral allergy syndrome or, in some cases, more severe systemic reactions. However, the clinical significance of this cross-reactivity is variable and not as well-documented as the pollen-food syndrome seen with birch (Bet v 1) or ragweed (profilin). Some patients with Parietaria allergy tolerate LTP-containing foods without symptoms, while others experience oral tingling, lip swelling, or even urticaria. Unlike profilin-mediated oral allergy syndrome, LTP reactions are not always heat-labile β€” cooked versions of the same foods may still cause reactions in highly sensitized individuals. Any patient with Parietaria allergy who experiences symptoms after eating should discuss LTP cross-reactivity with their allergist.

Foods to limit

  • Peach (LTP cross-reactivity)

    Peach LTP (Pru p 3) is structurally similar to Par j 1; may cause oral allergy syndrome or urticaria in Parietaria-sensitized patients.

  • Apple (LTP cross-reactivity)

    Apple LTP (Mal d 3) may cross-react with Par j 1; reactions can occur with both raw and cooked apple in highly sensitized individuals.

  • Hazelnut (LTP cross-reactivity)

    Hazelnut LTP (Cor a 8) shares structural homology with Par j 1; may cause oral symptoms or more severe reactions.

  • Peanut (LTP cross-reactivity)

    Peanut LTP (Ara h 9) is a potential cross-reactive allergen; patients with Parietaria allergy should be aware of this possibility.

FAQ

Frequently Asked Questions

Pellitory of the wall (Parietaria judaica) and stinging nettle (Urtica dioica) are both members of the Urticaceae family, but they cause very different clinical presentations. Stinging nettle causes a non-allergic contact urticaria through histamine and other irritants in its trichomes (stinging hairs) β€” this is a direct chemical irritation, not an IgE-mediated allergy. Pellitory of the wall, by contrast, does not have stinging hairs and causes respiratory allergy through its pollen, which contains the potent LTP allergen Par j 1. The plants look similar β€” both have small, inconspicuous flowers and similar leaf shapes β€” but pellitory of the wall lacks the stinging hairs that give nettle its name. Patients who experience skin irritation from touching nettle should not assume they are allergic to pellitory of the wall pollen, and vice versa.

Medical References

  1. [1]Colombo P, Bonura A, Costa MA, et al. The allergens of Parietaria. Allergy Asthma Proc 2003;24(3):173–177.
  2. [2]D'Amato G, Cecchi L, Bonini S, et al. Allergenic pollen and pollen allergy in Europe. Allergy 2007;62(9):976–990.
  3. [3]Liccardi G, D'Amato M, D'Amato G. Oleaceae and Parietaria pollens: a review of the most important allergens in the Mediterranean area. Eur Ann Allergy Clin Immunol 2005;37(1):25–30.
  4. [4]Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update. Allergy 2008;63 Suppl 86:8–160.
  5. [5]Costa MA, Colombo P, Izzo V, et al. cDNA cloning, expression and primary structure of Par j I, a major allergen of Parietaria judaica. FEBS Lett 1994;341(2-3):182–186.
  6. [6]Passalacqua G, Albano M, Fregonese L, et al. Randomised controlled trial of local allergoid immunotherapy for allergic rhinitis caused by Parietaria. Lancet 1998;351(9103):629–632.
  7. [7]Corsico R, Falagiani P, Ariano R, et al. Efficacy of sublingual immunotherapy for Parietaria judaica: a double-blind, placebo-controlled study. J Allergy Clin Immunol 1999;104(6):1200–1204.
  8. [8]Tharpe C, et al. Real-world outcomes of personalized sublingual immunotherapy for environmental allergies delivered through a telemedicine platform. Frontiers in Allergy. 2026;7:1865860.
  9. [9]Schaffer FM, Naples AR, Ebeling M, Hulsey TC, Garner LM. The safety of self-administered allergen immunotherapy during the buildup and maintenance phases. Int Forum Allergy Rhinol. 2015;5(2):149-156.

This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.

Get started today

Ready to treat your Pellitory of the Wall allergies for good?

Get a personalized treatment plan from board-certified allergists, delivered to your door.

Reviewed by board-certified allergists. Personalized treatment plans based on your at-home IgE test, not generic protocols.

Compare Curex plan pricing
3-minute quizBoard-certified allergistsProgram-specific pricing Β· Confirm your written quote

Questions about Curex itself?

Straight answers about the company, the evidence, what patients report, and what it costs β€” including the parts that are not flattering.

Find out what you're actually allergic to β€” and treat the cause

Take the free allergy quiz

Ready to treat your allergies at the source?

Take the free allergy quiz to find out if immunotherapy is right for you and get started with personalized treatment today.

Take Free Allergy Quiz